Arcutis Biotherapeutics reported earnings of $ 0.06 per ARQT share on Nov 4, 2026, falling short of analysts' expectations by
| Report Date | Nov 4, 2026 |
|---|---|
| Forecasted EPS | $ 0.18 |
| Earnings Per Share (Surprise) | $ 0.06 (-$ 0.12) |
| Last Year's EPS | -$ 0.04 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, Arcutis Biotherapeutics beat analysts’ expectations 18 times and fell short of expectations 10 time(s). Arcutis Biotherapeutics reported earnings per share of $ 0.06 in the last report falling to reach an estimated EPS of $ 0.18 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 4, 2026 | $ 0.18 | $ 0.06 | $ 0.06 | |
| Aug 5, 2026 | $ 0.05508 | $ 0.11 | -$ 0.13 | |
| May 6, 2026 | -$ 0.02 | -$ 0.09 | -$ 0.20 | |
| Feb 25, 2026 | $ 0.03 | $ 0.13 | -$ 0.09 | |
| Oct 28, 2025 | -$ 0.10 | $ 0.06 | -$ 0.33 | |
| Aug 6, 2025 | -$ 0.18 | -$ 0.13 | -$ 0.42 | |
| May 6, 2025 | -$ 0.21 | -$ 0.20 | -$ 0.32 | |
| Feb 25, 2025 | -$ 0.28 | -$ 0.09 | -$ 0.72 | |
| Nov 6, 2024 | -$ 0.42 | -$ 0.33 | -$ 0.73 | |
| Aug 14, 2024 | -$ 0.48 | -$ 0.42 | -$ 1.16 | |
| May 14, 2024 | -$ 0.60 | -$ 0.32 | -$ 1.31 | |
| Feb 27, 2024 | -$ 0.65 | -$ 0.72 | -$ 1.18 | |
| Nov 3, 2023 | -$ 0.90 | -$ 0.73 | -$ 1.89 | |
| Aug 8, 2023 | -$ 1.22 | -$ 1.16 | -$ 1.31 | |
| May 9, 2023 | -$ 1.30 | -$ 1.31 | -$ 1.27 | |
| Feb 28, 2023 | -$ 1.37 | -$ 1.18 | -$ 1.42 | |
| Nov 8, 2022 | -$ 1.54 | -$ 1.89 | -$ 1.14 | |
| Aug 4, 2022 | -$ 1.38 | -$ 1.31 | -$ 0.84 | |
| May 5, 2022 | -$ 1.42 | -$ 1.27 | -$ 0.76 | |
| Feb 22, 2022 | -$ 1.41 | -$ 1.42 | -$ 0.79 |
Arcutis Biotherapeutics’s stock was trading at $ 32.00 on Nov 3, 2026 a day before the last earnings report was released.Following the release of the earnings report, ARQT’s price decreased to $ 27.00 on Nov 5, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 4, 2026 | $ 0.06 | $ 32.00 | $ 27.00 | |
| Aug 5, 2026 | $ 0.11 | $ 26.03 | $ 26.43 | |
| May 6, 2026 | -$ 0.09 | $ 23.42 | $ 20.66 | |
| Feb 25, 2026 | $ 0.13 | $ 26.98 | $ 28.57 | |
| Oct 28, 2025 | $ 0.06 | $ 19.64 | $ 25.29 | |
| Aug 6, 2025 | -$ 0.13 | $ 15.33 | $ 14.12 | |
| May 6, 2025 | -$ 0.20 | $ 15.41 | $ 13.70 | |
| Feb 25, 2025 | -$ 0.09 | $ 12.39 | $ 13.22 | |
| Nov 6, 2024 | -$ 0.33 | $ 9.30 | $ 10.40 | |
| Aug 14, 2024 | -$ 0.42 | $ 9.95 | $ 8.50 | |
| May 14, 2024 | -$ 0.32 | $ 7.99 | $ 9.24 | |
| Feb 27, 2024 | -$ 0.72 | $ 9.69 | $ 10.41 | |
| Nov 3, 2023 | -$ 0.73 | $ 2.22 | $ 2.34 | |
| Aug 8, 2023 | -$ 1.16 | $ 9.58 | $ 9.39 | |
| May 9, 2023 | -$ 1.31 | $ 14.26 | $ 12.03 | |
| Feb 28, 2023 | -$ 1.18 | $ 15.98 | $ 16.69 | |
| Nov 8, 2022 | -$ 1.89 | $ 18.51 | $ 18.62 | |
| Aug 4, 2022 | -$ 1.31 | $ 22.21 | $ 25.15 | |
| May 5, 2022 | -$ 1.27 | $ 21.99 | $ 19.40 | |
| Feb 22, 2022 | -$ 1.42 | $ 15.98 | $ 16.15 |
Arcutis Biotherapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Arcutis Biotherapeutics missed analysts’ expectations during the last earnings period by
